Literature DB >> 27485057

Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.

Christos Agalianos1, Nikolaos Gouvas2, Kleo Papaparaskeva3, Christos Dervenis2.   

Abstract

BACKGROUND: The relation between para-aortic lymph nodes (PALN) involvement and pancreatic ductal adenocarcinoma (PDAC) survival, along with the optimal handling of this particular lymph node station remain unclear. A systematic review and meta-analysis was performed to assess this.
METHODS: A search of Medline, Embase, Ovid and Cochrane databases was performed until July 2015 to identify studies reporting on the relation of PALN involvement and PDAC outcomes and a meta-analysis was performed following data extraction.
RESULTS: Ten retrospective studies and two prospective non randomized studies (2467 patients) were included. Patients with positive PALN had worse one (p < 0.00001) and two year (p < 0.00001) survival when compared with patients with negative PALN. Even when comparing only patients with positive lymph nodes (N1), patients with PALN involvement presented with a significant lower one (p = 0.03) and two (p = 0.002) year survival. PALN involvement was associated with an increased possibility of positive margin (R1) resection (p < 0.00001), stations' 12, 14 and 17 malignant infiltration (p < 0.00001), but not with tumour stage (p = 0.78). DISCUSSION: Involvement of PALN is associated with decreased survival in pancreatic cancer patients. However, existence of long term survivors among this subgroup of patients should be further evaluated, in order to identify factors associated with their favourable prognosis.
Copyright © 2016 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27485057      PMCID: PMC4972380          DOI: 10.1016/j.hpb.2016.04.007

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  34 in total

1.  Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Yoshio Yuasa; Taijiro Sueda
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

2.  Retroportal lamina or mesopancreas? Lessons learned by anatomical and histological study of thirty three cadaveric dissections.

Authors:  Mahdi Bouassida; Mohamed Mongi Mighri; Mohamed Fadhel Chtourou; Selim Sassi; Hassen Touinsi; Hassen Hajji; Sadok Sassi
Journal:  Int J Surg       Date:  2013-08-28       Impact factor: 6.071

Review 3.  Mesopancreas: a boundless structure, namely R1 risk in pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  N Peparini; P Chirletti
Journal:  Eur J Surg Oncol       Date:  2013-10-25       Impact factor: 4.424

4.  Pancreatic resection for M1 pancreatic ductal adenocarcinoma.

Authors:  Shailesh V Shrikhande; Jörg Kleeff; Carolin Reiser; Jürgen Weitz; Ulf Hinz; Irene Esposito; Jan Schmidt; Helmut Friess; Markus W Büchler
Journal:  Ann Surg Oncol       Date:  2006-10-25       Impact factor: 5.344

5.  Para-aortic lymph node metastasis in carcinoma of the head of the pancreas.

Authors:  Mitsuru Sakai; Akimasa Nakao; Tetsuya Kaneko; Shin Takeda; Soichiro Inoue; Yasuhiro Kodera; Shuji Nomoto; Naohito Kanazumi; Hiroyuki Sugimoto
Journal:  Surgery       Date:  2005-06       Impact factor: 3.982

6.  Pancreatectomy with Para-Aortic Lymph Node Dissection for Pancreatic Head Adenocarcinoma: Pattern of Nodal Metastasis Spread and Analysis of Prognostic Factors.

Authors:  Salvatore Paiella; Giuseppe Malleo; Laura Maggino; Claudio Bassi; Roberto Salvia; Giovanni Butturini
Journal:  J Gastrointest Surg       Date:  2015-07-10       Impact factor: 3.452

7.  Reappraisal of Nodal Staging and Study of Lymph Node Station Involvement in Pancreaticoduodenectomy with the Standard International Study Group of Pancreatic Surgery Definition of Lymphadenectomy for Cancer.

Authors:  Giuseppe Malleo; Laura Maggino; Paola Capelli; Francesco Gulino; Silvia Segattini; Aldo Scarpa; Claudio Bassi; Giovanni Butturini; Roberto Salvia
Journal:  J Am Coll Surg       Date:  2015-02-28       Impact factor: 6.113

8.  Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma.

Authors:  Takanori Yoshida; Toshifumi Matsumoto; Atsushi Sasaki; Kohei Shibata; Masanori Aramaki; Seigo Kitano
Journal:  Am J Surg       Date:  2004-06       Impact factor: 2.565

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

10.  The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials.

Authors:  J Gaedcke; B Gunawan; M Grade; R Szöke; T Liersch; H Becker; B M Ghadimi
Journal:  Langenbecks Arch Surg       Date:  2009-05-06       Impact factor: 3.445

View more
  8 in total

1.  Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection.

Authors:  Sebastian Hempel; Verena Plodeck; Franz Mierke; Marius Distler; Daniela E Aust; Hans-Detlev Saeger; Jürgen Weitz; Thilo Welsch
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

2.  Para-aortic lymph node involvement should not be a contraindication to resection of pancreatic ductal adenocarcinoma.

Authors:  Rupaly Pande; Shafiq Chughtai; Manish Ahuja; Rachel Brown; David C Bartlett; Bobby V Dasari; Ravi Marudanayagam; Darius Mirza; Keith Roberts; John Isaac; Robert P Sutcliffe; Nikolaos A Chatzizacharias
Journal:  World J Gastrointest Surg       Date:  2022-05-27

3.  Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer.

Authors:  Cosimo Sperti; Mario Gruppo; Stella Blandamura; Michele Valmasoni; Gioia Pozza; Nicola Passuello; Valentina Beltrame; Lucia Moletta
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

Review 4.  Systemic Therapy for Metastatic Pancreatic Cancer.

Authors:  Thomas J Ettrich; Thomas Seufferlein
Journal:  Curr Treat Options Oncol       Date:  2021-10-19

5.  Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches

Authors:  Seung Eun Lee; Sung-Sik Han; Chang Moo Kang; Wooil Kwon; Kwang Yeol Paik; Ki Byung Song; Jae Do Yang; Jun Chul Chung; Chi-Young Jeong; Sun-Whe Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

6.  The prognostic relevance of examined lymph nodes for accurate staging of resected pancreatic adenocarcinoma.

Authors:  Claudia Zaharia; Marcus Roalsø; Kjetil Søreide
Journal:  Hepatobiliary Surg Nutr       Date:  2022-08       Impact factor: 8.265

Review 7.  Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens.

Authors:  Eline Soer; Lodewijk Brosens; Marc van de Vijver; Frederike Dijk; Marie-Louise van Velthuysen; Arantza Farina-Sarasqueta; Hans Morreau; Johan Offerhaus; Lianne Koens; Joanne Verheij
Journal:  Virchows Arch       Date:  2018-03-27       Impact factor: 4.064

8.  Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis.

Authors:  Christian Teske; Richard Stimpel; Marius Distler; Susanne Merkel; Robert Grützmann; Louisa Bolm; Ulrich Wellner; Tobias Keck; Daniela E Aust; Jürgen Weitz; Thilo Welsch
Journal:  Langenbecks Arch Surg       Date:  2021-03-13       Impact factor: 3.445

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.